Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The Eylea Market?

In the past few years, the Eylea market has experienced robust growth. The market size is projected to elevate from $9.94 billion in 2024 to $10.51 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. The historic period’s growth can be credited to the prevalence of Diabetic Macular Edema (DME), the clinical effectiveness and safety profile, its competitive edge over other anti-VEGF therapies, its approval for different retinal conditions, and the trend towards intravitreal injections.

The size of the Eylea market is projected to experience substantial expansion in the coming years, swelling to $13.64 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. This predicted growth for the forecasted period can be credited to factors such as the emergence of therapeutic indications, the arrival of biosimilar competition, the growth in awareness and diagnosis, real-world data and post-market research, and patient preference for less frequent injections. Key trends noted for the forecast period encompass advancements in imaging technologies, the proliferation of telemedicine and remote monitoring, patient assistance schemes, progress in drug delivery technologies, retinal imaging technologies, and clinical trials for innovative indications.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Growth-Enabling Forces Are Impacting The Eylea Market?

The rise in ocular disease cases is anticipated to boost the Eylea market. Ocular diseases, which directly impact one’s vision and the eye’s ability to function correctly, typically exhibit no symptoms until they are significantly advanced. Eylea is employed to deal with conditions such as these, including glaucoma and wet age-related macular degeneration (AMD), both of which cause retinal or macular damage and hinder vision. Eylea’s function involves obstructing the protein that instigates the creation of feeble new blood vessels and reduces swelling in the retina induced by obstructed blood vessels. Notably, in October 2022, the BrightFocus Foundation reported that there were approximately 80 million global glaucoma cases, with this number projected to increase to over 111 million by 2040. Consequently, the escalating occurrence of ocular diseases is a significant factor propelling the Eylea market.

How Is The Eylea Market Segmented Across Key Categories?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

What Key Trends Are Driving Growth In The Eylea Market?

Advancements in research are becoming an increasing trend in the Eylea market. Major industry players in Eylea are prioritizing the development of innovative technical solutions. For example, Regeneron Pharmaceuticals, Inc., a biotechnology company based in the US and focused on developing medications for severe illnesses, got the green light from the US FDA in August 2023 for their Eylea HD (aflibercept) injection 8 mg. This approval will help treat patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The approved treatment method begins with an interval of every four weeks for the first three months across all indications, before adjusting to eight to 16-week intervals for wAMD and DME and eight to 12 weeks for diabetic retinopathy.

Who Are The Leading Companies Driving The Eylea Market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Dominates The Eylea Market Today?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model